Improving supportive care of young patients with breast cancer
According to Prof. Ann Partridge, 2024 ESMO Awardee, young patients with breast cancer have unique needs that must be addressed to achieve better outcomes
Do young patients benefit from immune checkpoint inhibitors?
First evidence for the efficacy of anti-PD-1 agents in children, adolescents and young adults with melanoma prompts the call for a change in cancer care for this population
Cancer in old patients: geriatric assessment and management plays a crucial role to provide personalised care
First recommendations are released from the ESMO/SIOG Cancer in the Elderly Working Group
Tailoring care for LGBTQ patients with cancer – a long way ahead?
With a recent survey in collaboration with SIOPE and the recognition of LGBTQ as a specific patient population in the recommendations for a Global Curriculum in Medical Oncology, ESMO is at the forefront of a more inclusive oncology
Oncologists do not feel well-prepared to address the health needs of LGBTQ cancer patients
In an ESMO-SIOPE survey, only 10% of respondents report they received adequate education in medical school about how to tailor cancer care to this population
Health emergencies: let’s get prepared without leaving cancer patients behind
ESMO is advocating for secondary and tertiary care levels to be included into international agreements and WHO’s documents to respond to pandemics
Access to high-quality care for sarcomas is still unequal worldwide
Delays and poor patient journey are reported in resource-constrained countries, while awareness campaigns and healthcare service reorganisation have improved rare cancer management in more developed areas
COVID-19 vaccination is key to restoring early-phase anticancer drug development
Vaccination among cancer patients should not affect their participation in clinical trials and levels of acceptance of the vaccine are high
Optimising clinical trials for greater inclusiveness
Oncologists are aiming to capitalise on lessons learned from the COVID-19 pandemic and design more inclusive clinical trials, optimise trial endpoints and make better use of real-world evidence.
Innovation is creating new ways to support oncologists
How ESMO is transforming the challenges from the COVID-19 pandemic into opportunities to re-shape the future of the oncology community